DayTwo is the leading Microbiome-Based Precision Medicine company, developing personalized nutrition, diagnostic, and therapeutic solutions using artificial intelligence and machine learning. DayTwo has the largest full-shotgun database of the gut-microbiome in the world. The database is the foundation for the DayTwo Human Discovery Platform? to identify precision medicine therapies, diagnostics, and care solutions for metabolic and other diseases. Initial product enables glycemic-control helping type II diabetes patients to balance their blood sugar-levels personalized to the subject’s clinical and personal traits.